BACKGROUND: Recombinant factor VIIa (rFVIIa), a hemostatic agent approved for hemophilia, is increasingly used for off-label indications. PURPOSE: To evaluate the benefits and harms of rFVIIa use for 5 off-label, in-hospital indications: intracranial hemorrhage, cardiac surgery, trauma, liver transplantation, and prostatectomy. DATA SOURCES: Ten databases (including PubMed, EMBASE, and the Cochrane Library) queried from inception through December 2010. Articles published in English were analyzed. STUDY SELECTION: Two reviewers independently screened titles and abstracts to identify clinical use of rFVIIa for the selected indications and identified all randomized, controlled trials (RCTs) and observational studies for full-text review. DATA EXTRACTION: Two reviewers independently assessed study characteristics and rated study quality and indication-wide strength of evidence. DATA SYNTHESIS: 16 RCTs, 26 comparative observational studies, and 22 noncomparative observational studies met inclusion criteria. Identified comparators were limited to placebo (RCTs) or usual care (observational studies). For intracranial hemorrhage, mortality was not improved with rFVIIa use across a range of doses. Arterial thromboembolism was increased with medium-dose rFVIIa use (risk difference [RD], 0.03 [95% CI, 0.01 to 0.06]) and high-dose rFVIIa use (RD, 0.06 [CI, 0.01 to 0.11]). For adult cardiac surgery, there was no mortality difference, but there was an increased risk for thromboembolism (RD, 0.05 [CI, 0.01 to 0.10]) with rFVIIa. For body trauma, there were no differences in mortality or thromboembolism, but there was a reduced risk for the acute respiratory distress syndrome (RD, -0.05 [CI, -0.02 to -0.08]). Mortality was higher in observational studies than in RCTs. LIMITATIONS: The amount and strength of evidence were low for most outcomes and indications. Publication bias could not be excluded. CONCLUSION: Limited available evidence for 5 off-label indications suggests no mortality reduction with rFVIIa use. For some indications, it increases thromboembolism.
BACKGROUND: Recombinant factor VIIa (rFVIIa), a hemostatic agent approved for hemophilia, is increasingly used for off-label indications. PURPOSE: To evaluate the benefits and harms of rFVIIa use for 5 off-label, in-hospital indications: intracranial hemorrhage, cardiac surgery, trauma, liver transplantation, and prostatectomy. DATA SOURCES: Ten databases (including PubMed, EMBASE, and the Cochrane Library) queried from inception through December 2010. Articles published in English were analyzed. STUDY SELECTION: Two reviewers independently screened titles and abstracts to identify clinical use of rFVIIa for the selected indications and identified all randomized, controlled trials (RCTs) and observational studies for full-text review. DATA EXTRACTION: Two reviewers independently assessed study characteristics and rated study quality and indication-wide strength of evidence. DATA SYNTHESIS: 16 RCTs, 26 comparative observational studies, and 22 noncomparative observational studies met inclusion criteria. Identified comparators were limited to placebo (RCTs) or usual care (observational studies). For intracranial hemorrhage, mortality was not improved with rFVIIa use across a range of doses. Arterial thromboembolism was increased with medium-dose rFVIIa use (risk difference [RD], 0.03 [95% CI, 0.01 to 0.06]) and high-dose rFVIIa use (RD, 0.06 [CI, 0.01 to 0.11]). For adult cardiac surgery, there was no mortality difference, but there was an increased risk for thromboembolism (RD, 0.05 [CI, 0.01 to 0.10]) with rFVIIa. For body trauma, there were no differences in mortality or thromboembolism, but there was a reduced risk for the acute respiratory distress syndrome (RD, -0.05 [CI, -0.02 to -0.08]). Mortality was higher in observational studies than in RCTs. LIMITATIONS: The amount and strength of evidence were low for most outcomes and indications. Publication bias could not be excluded. CONCLUSION: Limited available evidence for 5 off-label indications suggests no mortality reduction with rFVIIa use. For some indications, it increases thromboembolism.
Authors: Philip W Friederich; Christiaan P Henny; Embert J Messelink; Mark G Geerdink; Tymen Keller; Karl-Heinz Kurth; Harry R Büller; Marcel Levi Journal: Lancet Date: 2003-01-18 Impact factor: 79.321
Authors: Piotr Kaliciński; Małgorzata Markiewicz; Andrzej Kamiński; Przemysław Laniewski; Hor Ismail; Tomasz Drewniak; Marek Szymczak; Paweł Nachulewicz; Elzbieta Jezierska Journal: Pediatr Transplant Date: 2005-06
Authors: Luigi Tritapepe; Vincenzo De Santis; Domenico Vitale; Cecilia Nencini; Fabio Pellegrini; Giovanni Landoni; Federico Toscano; Fabio Miraldi; Paolo Pietropaoli Journal: Crit Care Med Date: 2007-07 Impact factor: 7.598
Authors: Jason D Wright; Cande V Ananth; Sharyn N Lewin; William M Burke; Zainab Siddiq; Alfred I Neugut; Thomas J Herzog; Dawn L Hershman Journal: J Surg Res Date: 2013-08-13 Impact factor: 2.192
Authors: Santiago R Leal-Noval; Manuel Muñoz; Marisol Asuero; Enric Contreras; José A García-Erce; Juan V Llau; Victoria Moral; José A Páramo; Manuel Quintana Journal: Blood Transfus Date: 2013-06-17 Impact factor: 3.443
Authors: Jason M Elinoff; Ulas Bagci; Brad Moriyama; Jennifer L Dreiling; Brent Foster; Nicole J Gormley; Rachel B Salit; Rongman Cai; Junfeng Sun; Andrea Beri; Debra J Reda; Farhad Fakhrejahani; Minoo Battiwalla; Kristin Baird; Jennifer M Cuellar-Rodriguez; Elizabeth M Kang; Stephen Z Pavletic; Dan H Fowler; A John Barrett; Jay N Lozier; David E Kleiner; Daniel J Mollura; Richard W Childs; Anthony F Suffredini Journal: Biol Blood Marrow Transplant Date: 2014-03-20 Impact factor: 5.742
Authors: Paolo Feltracco; Marialuisa Brezzi; Stefania Barbieri; Helmut Galligioni; Moira Milevoj; Cristiana Carollo; Carlo Ori Journal: World J Hepatol Date: 2013-01-27
Authors: Donald H Jenkins; Joseph F Rappold; John F Badloe; Olle Berséus; Lorne Blackbourne; Karim H Brohi; Frank K Butler; Andrew P Cap; Mitchell Jay Cohen; Ross Davenport; Marc DePasquale; Heidi Doughty; Elon Glassberg; Tor Hervig; Timothy J Hooper; Rosemary Kozar; Marc Maegele; Ernest E Moore; Alan Murdock; Paul M Ness; Shibani Pati; Todd Rasmussen; Anne Sailliol; Martin A Schreiber; Geir Arne Sunde; Leo M G van de Watering; Kevin R Ward; Richard B Weiskopf; Nathan J White; Geir Strandenes; Philip C Spinella Journal: Shock Date: 2014-05 Impact factor: 3.454
Authors: Amanda Zatta; Zoe Mcquilten; Rangi Kandane-Rathnayake; James Isbister; Scott Dunkley; John Mcneil; Peter Cameron; Louise Phillips Journal: Blood Transfus Date: 2014-06-05 Impact factor: 3.443